Literature DB >> 3887669

Determination of total and free plasma carbamazepine concentrations by enzyme multiplied immunoassay: interference with the 10,11-epoxide metabolite.

M Contin, R Riva, F Albani, E Perucca, A Baruzzi.   

Abstract

The performance of the enzyme multiplied immunoassay technique (EMIT) in the measurement of total and free plasma carbamazepine (CBZ) levels was assessed in 140 clinical specimens and compared with a reference high pressure liquid chromatography (HPLC) technique. Free drug was measured in plasma filtrates obtained by the Free Level system. Both total and free CBZ levels as determined by EMIT correlated strongly with corresponding HPLC values (r = 0.88 and 0.92, respectively). Plasma CBZ concentrations, however, were higher by EMIT than by HPLC. The degree of CBZ overestimation by EMIT was relatively small (about 14%) in whole plasma but quite considerable (35% on average) in the filtrates. As a result, estimated values of free CBZ fraction were also higher for EMIT than for HPLC. Separate experiments in vitro suggested that the discrepancies between the two methods were due to cross-reaction of the EMIT reagent with the 10,11-epoxide metabolite of CBZ. The greater degree of overestimation for the free drug can be explained by the higher proportion of less protein-bound metabolite in the filtrates. These results need to be taken into account in the interpretation of free CBZ level data from laboratories using different techniques.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887669     DOI: 10.1097/00007691-198503000-00007

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

Review 1.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

2.  Carbamazepine and its metabolites in neuralgias: concentration-effect relations.

Authors:  R S Moosa; M L McFadyen; R Miller; J Rubin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.

Authors:  Y Kodama; K Tsutsumi; M Kuranari; H Kodama; I Fujii; M Takeyama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

5.  Altered serum protein binding of carbamazepine in disease states associated with an increased alpha 1-acid glycoprotein concentration.

Authors:  A Baruzzi; M Contin; E Perucca; F Albani; R Riva
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

7.  Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy.

Authors:  M Contin; R Riva; F Albani; E Perucca; G Lamontanara; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Two-Dimensional Metallic NiSe2 Nanoclusters-Based Low-Cost, Flexible, Amperometric Sensor for Detection of Neurological Drug Carbamazepine in Human Sweat Samples.

Authors:  Sushmitha Veeralingam; Sushmee Badhulika
Journal:  Front Chem       Date:  2020-04-30       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.